Aureomycin/Chlortetracycline

In the field of livestock and poultry farming, bacterial infectious diseases have always been one of the core risks that affect breeding efficiency and threaten animal health. Chlortetracycline belongs to the tetracycline class of broad-spectrum antibiotics. It reversibly binds to the 30S subunit of bacterial ribosomes, inhibits peptide chain elongation and protein synthesis, and has excellent inhibitory activity against Gram-positive bacteria, Gram-negative bacteria, mycoplasma, and rickettsia. Clinically, it is mainly used for the prevention and treatment of respiratory and digestive tract infections in livestock and poultry. Meanwhile, it can act as a growth promoter to improve feed conversion rate, and is a widely used anti-infective veterinary API in the livestock and poultry breeding industry chain.

The global chlortetracycline market size has maintained a steady growth trend in recent years. The market size was approximately USD 380 million in 2023, and is expected to reach USD 470 million by 2028, with a compound annual growth rate of about 4.2%. From the perspective of the competitive landscape, China is the world's largest producer and exporter of chlortetracycline, with its production capacity accounting for more than 85% of the global total capacity. Leading production enterprises are concentrated in North China and East China, and their products are mainly exported to Southeast Asia, South America, Europe and other regions with intensive breeding industries. In terms of centralized procurement, chlortetracycline has been included in the common veterinary drug procurement catalogs of multiple provinces in domestic centralized veterinary drug procurement, the winning bid prices are generally stable, and the downstream demand shows obvious rigid characteristics.

The original research enterprise of chlortetracycline is Pfizer Inc. of the United States, with the original brand name Aureomycin. The core compound patent expired globally in 1992. At present, the mainstream marketed dosage forms include premix, soluble powder and injection. Among them, premixes with 15% and 20% content are the core specifications used at the breeding end, which have been included in the FDA Veterinary Reference Preparation Catalog and also included in the *Chinese Veterinary Pharmacopoeia* 2025 edition. As of now, there are 12 valid registration numbers for chlortetracycline API on China's CDE API registration platform, 8 of which are in A status. More than 30 chlortetracycline preparation varieties have been approved for marketing in China, covering all mainstream dosage forms. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for chlortetracycline API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products comply with the regulatory requirements of the Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use needs of veterinary drug enterprises in the whole process of API R&D, quality control and registration declaration.